Repurposing Atomoxetine for Neuroprotection in MCI Repurposing Atomoxetine for Neuroprotection in MCI
Atomoxetine, approved for ADHD, can be repurposed as a safe and effective therapy for mild cognitive impairment and improves multiple biomarkers of Alzheimer ' s disease, according to this study.Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 19, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

SNRI'Shows Promise' for Comorbid ADHD, PTSD SNRI'Shows Promise' for Comorbid ADHD, PTSD
The SNRI atomoxetine may help improve outcomes for patients with both attention-deficit/hyperactivity disorder and posttraumatic stress disorder, new research suggests.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 22, 2021 Category: Internal Medicine Tags: Psychiatry News Source Type: news

Q & A: A drug-free option for treating ADHD in children
Deciding how to treat attention deficit hyperactivity disorder in children can be a difficult decision for parents. Stimulants, such as Adderall and Ritalin, are the most commonly prescribed ADHD treatments — and are considered to be the most effective.   But in April, the FDA approved the first device-based, non-drug therapy to treat ADHD in children. The FDA decision followed the completion of aUCLA study demonstrating the effectiveness and safety of a trigeminal nerve stimulation device that could be a new option for treating the disorder.The device tested in the study was developed using technology invented at UCLA...
Source: UCLA Newsroom: Health Sciences - November 5, 2019 Category: Universities & Medical Training Source Type: news

Medical News Today: What are the differences between Strattera and Vyvanse?
This article discusses their effects, risks, how to take them, and how to choose between the two. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 1, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Which Drugs Work Best for ADHD? Large Study Zeroes in on Two
The researchers compared seven ADHD drugs -- amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate and modafinil -- and a placebo over 12 weeks of treatment. (Source: WebMD Health)
Source: WebMD Health - August 8, 2018 Category: Consumer Health News Source Type: news

Unnecessary And Accidental Use Of ADHD Drugs Increases Over 60%, Study Suggests
(CNN) — Exposure to common medications used to treat attention deficit hyperactivity disorder has increased by more than 60% in US children and adolescents, according to a new study. The study, published Monday in the journal Pediatrics, looked at all calls to US poison control centers for unintentional or intentional exposure to ADHD medications between 2000 and 2014 among children and adolescents. The researchers found that the number of calls increased from 7,018 in 2000 to 11,486 in 2014 — a 64% increase. According to the study’s authors, “exposure” refers to the unnecessary ingestion, inh...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 21, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health ADHD Local TV Source Type: news

What Are the Side Effects of Strattera?
Title: What Are the Side Effects of Strattera?Category: Doctor's& Expert's views on SymptomsCreated: 6/8/2017 12:00:00 AMLast Editorial Review: 6/8/2017 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - June 8, 2017 Category: Pediatrics Source Type: news

D.C. Week: FDA Okays Generic Stattera, Insurance Stabilization Urged
(MedPage Today) -- FDA approves the first generic version of atomoxetine for treating ADHD (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 3, 2017 Category: American Health Source Type: news

FDA Approves Generic Atomoxetine for ADHD (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM The FDA has approved the first generic version … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 1, 2017 Category: Primary Care Source Type: news

Health Highlights: May 31, 2017
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Generic ADHD Drugs Approved by FDA The first generic versions of the attention-deficit/hyperactivity disorder (ADHD) drug Strattera (atomoxetine)... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 31, 2017 Category: General Medicine Source Type: news

FDA approves first generic Strattera for the treatment of ADHD
The U.S. Food and Drug Administration has approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited gained approval to market atomoxetine in multiple strengths. (Source: World Pharma News)
Source: World Pharma News - May 31, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Clears First Generic Versions of Strattera for ADHD FDA Clears First Generic Versions of Strattera for ADHD
Generic versions of atomoxetine for the treatment of ADHD in adults and children will be available in multiple strengths.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 30, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

ADHD: FDA OKs Strattera Generic
(MedPage Today) -- Four companies get green light to market (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 30, 2017 Category: Neurology Source Type: news

FDA approves first generic Strattera for the treatment of ADHD
The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 30, 2017 Category: American Health Source Type: news

FDA Approves First Generic Strattera for the Treatment of ADHD
May 30, 2017 -- The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Apotex Inc., Teva Pharmaceuticals... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 30, 2017 Category: Pharmaceuticals Source Type: news